276 related articles for article (PubMed ID: 26809529)
21. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma.
Woo HY; Bae SH; Park JY; Han KH; Chun HJ; Choi BG; Im HU; Choi JY; Yoon SK; Cheong JY; Cho SW; Jang BK; Hwang JS; Kim SG; Kim YS; Seo YS; Yim HJ; Um SH;
Cancer Chemother Pharmacol; 2010 Jan; 65(2):373-82. PubMed ID: 19763572
[TBL] [Abstract][Full Text] [Related]
22. Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
Kanekawa T; Nagai H; Kanayama M; Sumino Y
Cancer Chemother Pharmacol; 2014 Nov; 74(5):899-909. PubMed ID: 25138286
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers.
Miyaki D; Kawaoka T; Aikata H; Kan H; Fujino H; Fukuhara T; Kobayashi T; Naeshiro N; Honda Y; Tsuge M; Hiramatsu A; Imamura M; Hyogo H; Kawakami Y; Yoshimatsu R; Yamagami T; Awai K; Chayama K
J Gastroenterol Hepatol; 2015 Apr; 30(4):726-32. PubMed ID: 25311578
[TBL] [Abstract][Full Text] [Related]
24. Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma.
Shao YY; Huang CC; Liang PC; Lin ZZ
Asia Pac J Clin Oncol; 2010 Jun; 6(2):80-8. PubMed ID: 20565419
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
Yamasaki T; Kimura T; Kurokawa F; Aoyama K; Ishikawa T; Tajima K; Yokoyama Y; Takami T; Omori K; Kawaguchi K; Tsuchiya M; Terai S; Sakaida I; Okita K
J Gastroenterol; 2005 Jan; 40(1):70-8. PubMed ID: 15692792
[TBL] [Abstract][Full Text] [Related]
26. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB
Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870
[TBL] [Abstract][Full Text] [Related]
27. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
Ando E; Tanaka M; Yamashita F; Kuromatsu R; Yutani S; Fukumori K; Sumie S; Yano Y; Okuda K; Sata M
Cancer; 2002 Aug; 95(3):588-95. PubMed ID: 12209752
[TBL] [Abstract][Full Text] [Related]
28. Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib.
Nishiofuku H; Tanaka T; Anai H; Sueyoshi S; Maeda S; Masada T; Kichikawa K
Anticancer Res; 2012 Sep; 32(9):4121-4. PubMed ID: 22993371
[TBL] [Abstract][Full Text] [Related]
29. Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy.
Yamashita T
Clin Drug Investig; 2012 Aug; 32 Suppl 2():15-23. PubMed ID: 22873624
[TBL] [Abstract][Full Text] [Related]
30. Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy.
Saeki I; Yamasaki T; Maeda M; Hisanaga T; Iwamoto T; Matsumoto T; Hidaka I; Ishikawa T; Takami T; Sakaida I
PLoS One; 2019; 14(6):e0218136. PubMed ID: 31194789
[TBL] [Abstract][Full Text] [Related]
31. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma.
Ueshima K; Kudo M; Takita M; Nagai T; Tatsumi C; Ueda T; Kitai S; Ishikawa E; Yada N; Inoue T; Hagiwara S; Minami Y; Chung H
Oncology; 2010 Jul; 78 Suppl 1():148-53. PubMed ID: 20616598
[TBL] [Abstract][Full Text] [Related]
32. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Eun JR; Lee HJ; Moon HJ; Kim TN; Kim JW; Chang JC
Scand J Gastroenterol; 2009; 44(12):1477-86. PubMed ID: 19958061
[TBL] [Abstract][Full Text] [Related]
33. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification.
Miyaki D; Aikata H; Honda Y; Naeshiro N; Nakahara T; Tanaka M; Nagaoki Y; Kawaoka T; Takaki S; Waki K; Hiramatsu A; Takahashi S; Ishikawa M; Kakizawa H; Awai K; Chayama K
J Gastroenterol Hepatol; 2012 Dec; 27(12):1850-7. PubMed ID: 23020312
[TBL] [Abstract][Full Text] [Related]
34. Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular Carcinoma.
Shakado S; Iwata K; Tsuchiya N; Kunimoto H; Yotsumoto K; Fukunaga A; Kuno S; Tanaka T; Sakurai K; Iwashita H; Hirano G; Yokoyama K; Morihara D; Nishizawa S; Takeyama Y; Irie M; Sohda T; Kora S; Yoshimitsu K; Sakisaka S
Hepatogastroenterology; 2014 May; 61(131):557-62. PubMed ID: 26176035
[TBL] [Abstract][Full Text] [Related]
35. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
Masuda K; Ono A; Aikata H; Kawaoka T; Nelson Hayes C; Teraoka Y; Daijo K; Nakamura-Inagaki Y; Morio K; Fujino H; Kan H; Uchida T; Masaki K; Kobayashi T; Nakahara T; Makokha GN; Zhang Y; Nagaoki Y; Miki D; Tsuge M; Hiramatsu A; Imamura M; Abe-Chayama H; Kawakami Y; Ochi H; Chayama K
J Gastroenterol; 2018 Jan; 53(1):107-118. PubMed ID: 28474222
[TBL] [Abstract][Full Text] [Related]
36. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis.
Liu M; Shi J; Mou T; Wang Y; Wu Z; Shen A
J Gastroenterol Hepatol; 2020 Aug; 35(8):1277-1287. PubMed ID: 32052876
[TBL] [Abstract][Full Text] [Related]
37. Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
Han S; Choi HJ; Beom SH; Kim HR; Lee H; Lee JS; Lee HW; Park JY; Kim SU; Kim DY; Ahn SH; Han KH; Seong J; Won JY; Kim BK
J Cancer Res Clin Oncol; 2021 Oct; 147(10):3123-3133. PubMed ID: 33893539
[TBL] [Abstract][Full Text] [Related]
38. Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article.
Kang MK; Park JG; Lee HJ
Medicine (Baltimore); 2018 Apr; 97(17):e0611. PubMed ID: 29703062
[TBL] [Abstract][Full Text] [Related]
39. Pathological complete response by advanced hepatocellular carcinoma with massive macrovascular invasion to hepatic arterial infusion chemotherapy: a case report.
Sano S; Nakata S; Wada S; Kuroiwa M; Sakai H; Kusama K; Machida T; Nishio A; Ito I; Sodeyama H
World J Surg Oncol; 2019 Dec; 17(1):229. PubMed ID: 31878937
[TBL] [Abstract][Full Text] [Related]
40. A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy.
Shao YY; Liang PC; Wu YM; Huang CC; Huang KW; Cheng JC; Hsu CH; Hsu C; Cheng AL; Lin ZZ
Liver Int; 2013 Oct; 33(9):1413-9. PubMed ID: 23714197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
